Dimensional Analysis of CD44High CD24Low and Ki67 in Triple Negative Breast Cancer
DOI:
https://doi.org/10.3889/oamjms.2019.182Keywords:
Triple-negative breast cancer, Stemness, Differentiation, EMT, CD44, CD24Abstract
AIM: To study the dimensional analysis CD44high CD24low and Ki67 in triple negative breast cancer (TNBC).
METHODS: This cross-sectional study was performed on patients with breast cancer in Haji Adam Malik Hospital Medan from 2013 to 2016 to determine the frequency and pathologic features of TNBC by immunohistochemistry stained.
RESULTS: By using immunohistochemistry staining panel of CD44, CD24, Twist, Claudin 7, CK5, CK8/18, EMA, E-Cadherin, Ki-67, a total 67 breast tumour samples with TNBC were classified as 9 stem-cells like 1 basal, 22 baso-luminal, and 23 luminal subtypes
CONCLUSION: By using immunohistochemical staining panel, TNBC can be differentiated into stem cells like basal, baso-luminal and luminal subtypes. Didifferentiation and EMT can produce heterogeneity in TNBC subtypes and this will affect in handling TNBC. Stemness in stem cells- like subtypes are resistant to therapy. Therefore, TNBC needs special attention in order to assist in more optimal handling.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Li, Z, Tognon CE, Godinho FJ. ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. Cancer Cell. 2017; 12:542-58. https://doi.org/10.1016/j.ccr.2007.11.012 PMid:18068631 PMCid:PMC2175032
Morrison BJ, Schmidt CW, Lakhani SR, Brent A, Reynolds BA, Lopez JA. Breast cancer stem cells: implications for therapy of breast cancer. Breast Cancer Research. 2018; 10(4):210. https://doi.org/10.1186/bcr2111 PMid:18671830 PMCid:PMC2575525
Leung ELH, Fiscus RR, Tung JW. Non-small cell lung cancer cells expressing CD44 are enriched for stem celllike properties. PLoS ONE. 2010; 5(11). https://doi.org/10.1371/journal.pone.0014062
Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cellular and Molecular Immunology. 2010; 7(2):100-3. https://doi.org/10.1038/cmi.2009.119 PMid:20154703 PMCid:PMC4001892
Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, et al. Invasive ductal carcinoma of the breast with the "triplenegative" phenotype: prognostic implications of EGFR immunoreactivity. Breast Cancer Res Treat. 2009; 116:317-28. https://doi.org/10.1007/s10549-008-0206-z PMid:18839307
Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke C, Soares F, Brentani MM. Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer. Oncology Reports. 2011; 27:28-38. PMid:21956537
Kyo S, Sakaguchi J, Ohno S. High Twist expression is involved in infiltrative endometrial cancer and affects patient survival. Hum Pathol. 2006; 37:431-8. https://doi.org/10.1016/j.humpath.2005.12.021 PMid:16564917
Singhai R, Patil VW, Jaiswal SR, Patil SD, Tayade MB, Patil AV. E-Cadherin as a diagnostic biomarker in breast cancer. N Am J Med Sci. 2011; 3(5):227-33. https://doi.org/10.4297/najms.2011.3227 PMid:22558599 PMCid:PMC3337742
Saidi RF, Remine SG, Jacobs MJ. Interferon receptor alpha/beta is associated with improved survival after adjuvant therapy in resected pancreatic cancer. HPB. 2007; 9:289-94. https://doi.org/10.1080/13651820701329241 PMid:18345307 PMCid:PMC2215399
Cheang MC, Chia SK, Voduc D. Ki-67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009; 101:736-50. https://doi.org/10.1093/jnci/djp082 PMid:19436038 PMCid:PMC2684553
Idowu MO, Kmieciak M, Dumur C. "CD44+/CD24−/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome." Human Pathology. 2012; 43(3):364-73. https://doi.org/10.1016/j.humpath.2011.05.005 PMid:21835433
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Betty Tan, Mpu Kanoko, Gino Tan, Adang Bachtiar, Delfitri Munir
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0